<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058937</url>
  </required_header>
  <id_info>
    <org_study_id>BSMO2020-2</org_study_id>
    <nct_id>NCT05058937</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre</brief_title>
  <acronym>BALLETT</acronym>
  <official_title>A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre - Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Belgian Society of Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Illumina, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OncoDNA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PierianDx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Belgian Society of Medical Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project, called &quot;BALLETT&quot; (Belgian Approach of Local Laboratory Extensive Tumor Testing),&#xD;
      has a double goal: (1) show the relevance of broad molecular profiling to improve oncological&#xD;
      patients care, (2) demonstrate that broad molecular testing can be performed in a&#xD;
      decentralized setting by local diagnostics laboratories in a fully standardized and uniform&#xD;
      way while complying with the highest quality standards.&#xD;
&#xD;
      This 2-year study involves the consortium of 9 cooperating Belgian NGS laboratories and will&#xD;
      enroll 936 metastatic or locally advanced cancer patients coming from 13 different Belgian&#xD;
      hospitals and cancer centers. Upon inclusion, all cancer patients will be offered&#xD;
      'comprehensive genomic profiling' (CGP) using Illumina's TSO500 NGS panel. This targeted NGS&#xD;
      panel of 523 genes allows for the detection of single nucleotide variants, small indels, copy&#xD;
      number variations and fusions, as well as for the determination of the 'tumor mutational&#xD;
      burden' (TMB) and the 'microsatellite-instability' status (MSI). Both the wet lab execution&#xD;
      of the CGP as well as the biological and clinical classification of the variants will be&#xD;
      performed in a fully standardized way among the 9 participating Belgian local NGS&#xD;
      laboratories.&#xD;
&#xD;
      The CGP results will be interpreted and discussed in the weekly meeting of the BALLETT&#xD;
      national molecular tumor board (MTB), composed of oncologists, pathologists, molecular&#xD;
      biologists, geneticists and bioinformaticians. The MTB will provide recommendations for&#xD;
      targeted or immunotherapy based on the CGP results. Clinical Decision Support platforms&#xD;
      OncoKDM (OncoDNA) and Clinical Genomics Workspace (PierianDx), both expert software that&#xD;
      turns NGS data into actionable clinical information, will be used. The resulting therapy&#xD;
      recommendation may consist of an approved therapy, a clinical trial, a medical need program&#xD;
      or off-label use of cancer drugs. Treating physicians will receive the MTB recommendations&#xD;
      and decide on the actual management of their patients. Reasons for not following the MTB&#xD;
      recommendation will be registered.&#xD;
&#xD;
      The objectives of the project are:&#xD;
&#xD;
        1. To evaluate the clinical value of CGP in &quot;real-world&quot; practice in giving patients with&#xD;
           advanced/metastatic solid tumours broader access to precision medicine&#xD;
&#xD;
        2. To describe the landscape of genomic alterations and quantify the actionable variants&#xD;
           detected by comprehensive panel testing&#xD;
&#xD;
        3. To evaluate the number of actionable variants that would have been missed if the NGS&#xD;
           analysis was limited to the reimbursed NGS panel (ComPerMed panel).&#xD;
&#xD;
        4. To assess the technical success of CGP&#xD;
&#xD;
        5. To standardize CGP data analysis, clinical interpretation, therapy recommendation and&#xD;
           reporting among participating laboratories to the highest extent possible&#xD;
&#xD;
        6. To describe and to quantify the uptake of treatments and the inclusion in clinical&#xD;
           trials recommended by the molecular tumour board guided by the CGP&#xD;
&#xD;
        7. To assess clinical benefit by calculating PFS ratio for individual patients (PFS on&#xD;
           CGP-selected therapy/PFS on prior therapy) (null hypothesis: ≤ 15% of patient population&#xD;
           has PFS ratio of ≥ 1.3)&#xD;
&#xD;
        8. To work in a multi-stakeholder approach to attract more innovative treatments and&#xD;
           clinical trials in Belgium&#xD;
&#xD;
        9. To establish a Belgian genomic tumor database under the authority of the governmental&#xD;
           'Sciensano' thereby increasing public health knowledge in Belgium&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number/prevalence of variants with clinical significance</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number/prevalence of variants with a classification of clinical significance Tier 1A or 1B (strong clinical significance) and Tier 2C and 2D (potential clinical significance) using CGP versus local NGS testing (if available) and/or versus minimally required ComPerMed panel.&#xD;
Tiering according to Li et al. AMP/ASCO/CAP. J Mol Diagn 19:4-23, 2017.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number/prevalence of alterations by type (SNVs, CNVs, fusions)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of patient journey</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Percentage of patients with MTB recommendation categorized according to variant-therapy match scoring system, percentage of patients accessing genotype-informed treatment, turnaround time from CGP request to MTB recommendation, proportion of patients accessing molecular guided therapy or immune checkpoint inhibitors or combinations based on the result of CGP, timing of treatment initiation following MTB recommendation, proportion of deviations from treatment recommendations and reasons (rapid clinical deterioration, other protocol, patient ineligible, off-label treatment unavailable, clinical trial not feasible (e.g. physical distance), clinical trial not recruiting, physician's decision, patient's choice, …)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with successful CGP</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS ratio</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>PFS based on RECIST 1.1 evaluation of patients on the CGP recommended therapy and PFS ratio (PFS on CGP-selected therapy/PFS on prior therapy) (null hypothesis: ≤ 15% of patient population has PFS ratio of ≥ 1.3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participating NGS laboratories continuing CGP after the study</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Including cost calculation and reimbursement data to support economic analysis (microcosting from the lab perspective and budget impact from the payer's perspective).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">936</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Comprehensive genomic profiling</intervention_name>
    <description>TSO500 (523 genes + MTB + MSI)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18 years and above)&#xD;
&#xD;
          -  Patients with metastatic solid tumours that are candidates for systemic therapy (early&#xD;
             lines are preferred). Numbers will be capped for frequent tumour types (breast cancer:&#xD;
             120 patients, NSCLC: 120 patients, colorectal cancer: 120 patients). There will be a&#xD;
             cohort of 150 patients with rare tumours or tumours with rare histology (Eur. J.&#xD;
             Cancer 2011; 47: 2493-2511). Patients will be recruited as they appear in clinical&#xD;
             practice.&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks.&#xD;
&#xD;
          -  Patient showing an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤&#xD;
             2.&#xD;
&#xD;
          -  Patients eligible for reimbursed NGS (cfr. indications NGS convention) will also be&#xD;
             tested by the local NGS panel although this is not required if the CGP is ISO 15189&#xD;
             accredited. In that situation, the CGP is considered the local NGS. Patients that are&#xD;
             not eligible for reimbursed NGS testing may only be tested by CGP.&#xD;
&#xD;
          -  Patients must have enough tissue from a metastatic (preferred) or primary lesion&#xD;
             biopsy for local testing and CGP testing, sufficient to extract a minimum of 80 ng DNA&#xD;
             diluted in TE 1x and 40-80 ng (80 ng recommended) RNA diluted in RNA-grade water for&#xD;
             TSO500 library prep. The nucleic acid extract must meet the quality requirements&#xD;
             specified in the protocol (See &quot;TruSight Oncology 500 (TSO500) workflow - Workflow&#xD;
             instructions for participant laboratories&quot;). The tissue should not be more than 2&#xD;
             years-old and fixed in 10% neutral buffered formalin. Availability of metastatic&#xD;
             biopsies retrieved after a previous therapy line are mandatory for patients treated&#xD;
             with therapies that are known to induce acquired mechanisms of resistance (EGFR TKIs&#xD;
             in NSCLC, aromatase inhibitors in breast cancer, TKIs in GIST…). Bone biopsies that&#xD;
             undergo decalcification are not allowed.&#xD;
&#xD;
          -  Patients can only be enrolled if they are also concomitantly registered in the&#xD;
             Precision-1 study and the investigator agrees to subsequent registration of CGP-driven&#xD;
             treatment given and the investigator assessed outcome on this and prior treatment (PFS&#xD;
             based on RECIST 1.1 evaluation).&#xD;
&#xD;
          -  Patients able to provide written informed consent prior to enrolment into a potential&#xD;
             subsequent clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of less than 12 weeks.&#xD;
&#xD;
          -  Inability to comply with protocol procedures.&#xD;
&#xD;
          -  Known presence of severe hematopoietic, renal, and/or hepatic dysfunction (according&#xD;
             to the local PI).&#xD;
&#xD;
          -  No informed consent provided.&#xD;
&#xD;
          -  Patient is not enrolled and followed as provided in Precision-1.&#xD;
&#xD;
          -  Insufficient DNA/RNA quantity (&lt;80 ng DNA, &lt;40-80 ng RNA) and quality (dCq value &gt;5&#xD;
             for DNA, DV200 value &lt;20% for RNA), (See &quot;TruSight Oncology 500 (TSO500) workflow -&#xD;
             Workflow instructions for participant laboratories&quot;).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brigitte Maes, Dr</last_name>
    <phone>+32 11 33 83 41</phone>
    <email>Brigitte.Maes@jessazh.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gordana Raicevic Toungouz</last_name>
    <email>Gordana.RaicevicToungouz@sciensano.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASZ Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max Schreuer</last_name>
      <email>Max.Schreuer@asz.be</email>
    </contact>
    <investigator>
      <last_name>Max Schreuer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joke van Gaelen</last_name>
      <email>ctuklinischestudies@zna.be</email>
    </contact>
    <investigator>
      <last_name>Joanna Vermeij, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Horemans</last_name>
      <phone>+32 3 443 37 59</phone>
      <email>jo.horemans@gza.be</email>
    </contact>
    <investigator>
      <last_name>Annemie Rutten, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lies Pottel</last_name>
      <email>ctc@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Jacques Van Huysse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanessa Fastenaekels</last_name>
      <phone>+32 2 474 94 78</phone>
      <email>Vanessa.Fastenaekels@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Malika Tahiri</last_name>
      <phone>+32 2 474 94 78</phone>
      <email>Malika.Tahiri@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Lore Decoster, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie Warnon</last_name>
      <phone>+32 71 10 47 47</phone>
      <email>Stephanie.WARNON@ghdc.be</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc Canon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Lenaerts</last_name>
      <email>julia.lenaerts@uza.be</email>
    </contact>
    <investigator>
      <last_name>Hans Prenen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lore Vansteelant</last_name>
      <email>Lore.Vansteelant@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Sylvie Rottey, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Tullen</last_name>
      <phone>+32 11 33 79 91</phone>
      <email>ann.tullen@jessazh.be</email>
    </contact>
    <investigator>
      <last_name>Jeroen Mebis, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Vanden Bempt</last_name>
      <email>isabelle.vandenbempt@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Sabine Tejpar, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Adriaens</last_name>
      <email>sophie.adriaens@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Francesca Dedeurwaerdere, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Decoster</last_name>
    </contact>
    <contact_backup>
      <email>lynn.decoster@azturnhout.be</email>
    </contact_backup>
    <investigator>
      <last_name>Lynn Decoster, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Comprehensive genomic profiling</keyword>
  <keyword>Next generation sequencing</keyword>
  <keyword>Tumor mutational burden</keyword>
  <keyword>Mircosatellite instability</keyword>
  <keyword>Molecular tumor board</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Actionable variants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

